Shots:

• The P-III TANGO study involves assessing of Tivicay (dolutegravir) + Epivir (lamivudine) vs tenofovir alafenamide fumarate (TAF) -containing regimen in patients with HIV-1 with maintained viral suppression for at least 6mos. on TAF containing regimen
• The P-III TANGO study resulted in meeting its 1 EPs i.e- patients with plasma HIV-1 RNA ≥50 c/mL using the FDA snapshot algorithm @48wks.- no case of virologic withdrawal or resistance is observed
• Tivicay (50mg) + Epivir (300mg) is a combination of INI and NRTI and has received approval in the US & EU for the treatment of HIV-1 infection with no ARV treatment history and no resistance to dolutegravir/lamivudine & INI class/lamivudine respectively

Click here to read full press release/ article | Ref: GSK | Image: Apex